Helix BioMedix, Inc. (HXBM)

OTCMKTS · Delayed Price · Currency is USD
7.18
-0.01 (-0.14%)
At close: Mar 5, 2025
-69.14%
Market Cap 1.61M
Revenue (ttm) 2.07M
Net Income (ttm) -2.58M
Shares Out 224.71K
EPS (ttm) -15.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 100
Average Volume 233
Open 7.18
Previous Close 7.19
Day's Range 7.18 - 7.18
52-Week Range 7.18 - 23.50
Beta 0.48
RSI 20.09
Earnings Date n/a

About Helix BioMedix

Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1988
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol HXBM
Full Company Profile

Financial Performance

In 2011, Helix BioMedix's revenue was $1.89 million, an increase of 122.07% compared to the previous year's $851,683. Losses were -$2.49 million, -67.73% less than in 2010.

Financial Statements

News

There is no news available yet.